首页 | 本学科首页   官方微博 | 高级检索  
     


The genetic toxicology of putative nongenotoxic carcinogens
Affiliation:1. Department of Transplantation, Mayo Clinic, Jacksonville, FL 32224, USA;2. Florida State University, Tallahassee, FL 32306, USA;3. Department of Molecular and Translational Medicine, University of Brescia, Brescia 25133, Italy;4. Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA;5. Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA;6. Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA;7. Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida, Jacksonville, FL 32224, USA;8. Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL 32224, USA
Abstract:This report examines a group of putative nongenotoxic carcinogens that have been cited in the published literature. Using short-term test data from the U.S. Environmental Protection Agency/International Agency for Research on Cancer genetic activity profile (EPA/IARC GAP) database we have classified these agents on the basis of their mutagenicity emphasizing three genetic endpoints: gene mutation, chromosomal aberration and aneuploidy. On the basis of results of short-term tests for these effects, we have defined criteria for evidence of mutagenicity (and nonmutagenicity) and have applied these criteria in classifying the group of putative nongenotoxic carcinogens. The results from this evaluation based on the EPA/IARC GAP database are presented along with a summary of the short-term test data for each chemical and the relevant carcinogenicity results from the NTP, Gene-Tox and IARC databases. The data clearly demonstrate that many of the putative nongenotoxic carcinogens that have been adequately tested in short-term bioassays induce gene or chromosomal mutations or aneuploidy.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号